首页 > 最新文献

Clinical calcium最新文献

英文 中文
[Association between osteoporosis and atherosclerosis in dyslipidemia.] [血脂异常患者骨质疏松与动脉粥样硬化的关系]
Pub Date : 2019-01-01 DOI: 10.20837/4201902237
Nobuyuki Tai, Daisuke Inoue
Age-related osteoporosis and atherosclerosis is promoted by life style-related diseases such as dyslipidemia and diabetes mellitus. Common factors pathophysiologically involved in both osteoporosis and vascular calcification include senescent cells and osteoprotegerin(OPG). Dyslipidemia may impair both osteoclast and osteoblast function,thereby causing osteoporosis. Statins may have favorable effect on bone. Some anti-osteoporotic medications have also been suggested to show protective effect from atherosclerosis.
与生活方式有关的疾病,如血脂异常和糖尿病,可促进与年龄有关的骨质疏松症和动脉粥样硬化。参与骨质疏松和血管钙化的常见病理生理因素包括衰老细胞和骨保护素(OPG)。血脂异常可损害破骨细胞和成骨细胞的功能,从而引起骨质疏松。他汀类药物可能对骨骼有益。一些抗骨质疏松药物也被认为对动脉粥样硬化有保护作用。
{"title":"[Association between osteoporosis and atherosclerosis in dyslipidemia.]","authors":"Nobuyuki Tai, Daisuke Inoue","doi":"10.20837/4201902237","DOIUrl":"https://doi.org/10.20837/4201902237","url":null,"abstract":"Age-related osteoporosis and atherosclerosis is promoted by life style-related diseases such as dyslipidemia and diabetes mellitus. Common factors pathophysiologically involved in both osteoporosis and vascular calcification include senescent cells and osteoprotegerin(OPG). Dyslipidemia may impair both osteoclast and osteoblast function,thereby causing osteoporosis. Statins may have favorable effect on bone. Some anti-osteoporotic medications have also been suggested to show protective effect from atherosclerosis.","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 2","pages":"237-243"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36895577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Regulation of osteoblasts and chondrocytes by Wnt signaling.] [Wnt信号对成骨细胞和软骨细胞的调控]
Pub Date : 2019-01-01 DOI: 10.20837/4201903299
Riko Nishimura, Kenji Hata, Jumpei Kida

Wnt plays important roles in regulation of differentiation of osteoblast and chondrocyte and their function. Wnt family members ingeniously utilize canonical Wnt signaling pathway through β-catenin and non-canonical Wnt signaling pathway independent of β-catenin, consequently regulating development, formation and homeostasis of bone and cartilage. Recent studies revealed that canonical Wnt signal activates transcriptional regulator, TAZ, in addition to transcription factors, LEF and TCF. Canonical Wnt signal crosstalks with BMP signal by stimulating complex formation of LEF1, TAZ and Runx2. Although molecular mechanism of non-canonical Wnt signal is getting clearer, the precise role of non-canonical Wnt signal in bone and cartilage seems still elusive.

Wnt在调节成骨细胞和软骨细胞的分化及其功能中起重要作用。Wnt家族成员巧妙地利用通过β-catenin的典型Wnt信号通路和不依赖于β-catenin的非典型Wnt信号通路,从而调节骨软骨的发育、形成和稳态。近年来的研究表明,典型Wnt信号除了激活转录因子LEF和TCF外,还激活转录调节因子TAZ。典型Wnt信号通过刺激LEF1、TAZ和Runx2复合物的形成与BMP信号串扰。尽管非典型Wnt信号的分子机制越来越清晰,但非典型Wnt信号在骨和软骨中的确切作用仍然难以捉摸。
{"title":"[Regulation of osteoblasts and chondrocytes by Wnt signaling.]","authors":"Riko Nishimura,&nbsp;Kenji Hata,&nbsp;Jumpei Kida","doi":"10.20837/4201903299","DOIUrl":"https://doi.org/10.20837/4201903299","url":null,"abstract":"<p><p>Wnt plays important roles in regulation of differentiation of osteoblast and chondrocyte and their function. Wnt family members ingeniously utilize canonical Wnt signaling pathway through β-catenin and non-canonical Wnt signaling pathway independent of β-catenin, consequently regulating development, formation and homeostasis of bone and cartilage. Recent studies revealed that canonical Wnt signal activates transcriptional regulator, TAZ, in addition to transcription factors, LEF and TCF. Canonical Wnt signal crosstalks with BMP signal by stimulating complex formation of LEF1, TAZ and Runx2. Although molecular mechanism of non-canonical Wnt signal is getting clearer, the precise role of non-canonical Wnt signal in bone and cartilage seems still elusive.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 3","pages":"299-307"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37007572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
[Fracture management and current concepts related to pregnancy-associated osteoporosis.] [骨折管理和妊娠相关性骨质疏松症的最新概念]
Pub Date : 2019-01-01 DOI: CliCa19017884
Koji Ishikawa, Takashi Nagai, Takuma Kuroda, Yoshifumi Kudo, Tomoaki Toyone, Katsunori Inagaki

Pregnancy-associated osteoporosis is a rare condition characterized by a transient but significant reduction in bone mineral density. To date, the underlying pathophysiological mechanisms remain unclear. Related symptoms include severe back or hip pain secondary to vertebral fractures and/or transient osteoporosis of the hip, which typically occur during the third trimester or during lactation. Although most women are managed conservatively, a few women need surgery. Prompt diagnosis and appropriate treatment is important not only for pain control, but also to improve the woman's future quality of life.

妊娠相关性骨质疏松症是一种罕见的疾病,其特征是短暂但显著的骨矿物质密度降低。迄今为止,潜在的病理生理机制尚不清楚。相关症状包括继发于椎体骨折和/或髋关节短暂性骨质疏松症的严重背部或髋关节疼痛,通常发生在妊娠晚期或哺乳期。虽然大多数女性都采取了保守治疗,但也有少数女性需要手术治疗。及时诊断和适当治疗不仅对控制疼痛很重要,而且对改善妇女未来的生活质量也很重要。
{"title":"[Fracture management and current concepts related to pregnancy-associated osteoporosis.]","authors":"Koji Ishikawa,&nbsp;Takashi Nagai,&nbsp;Takuma Kuroda,&nbsp;Yoshifumi Kudo,&nbsp;Tomoaki Toyone,&nbsp;Katsunori Inagaki","doi":"CliCa19017884","DOIUrl":"https://doi.org/CliCa19017884","url":null,"abstract":"<p><p>Pregnancy-associated osteoporosis is a rare condition characterized by a transient but significant reduction in bone mineral density. To date, the underlying pathophysiological mechanisms remain unclear. Related symptoms include severe back or hip pain secondary to vertebral fractures and/or transient osteoporosis of the hip, which typically occur during the third trimester or during lactation. Although most women are managed conservatively, a few women need surgery. Prompt diagnosis and appropriate treatment is important not only for pain control, but also to improve the woman's future quality of life.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"78-84"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36808012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Calcium Metabolism and Skeletal Changes during Pregnancy and Lactation.] [孕期和哺乳期钙代谢和骨骼变化]
Pub Date : 2019-01-01 DOI: CliCa19011926
Shun Yasuda, Hideki Mizunuma

Calcium metabolism changes dramatically during pregnancy and lactation because offspring needs a supply of calcium. Approximately 30g of calcium, which passes through the placenta, is accumulated in a fetus during pregnancy mostly in the third trimester, and 220-340mg/day of calcium is supplied via breast milk during lactation. However, there are elaborate mechanisms to maintain maternal calcium homeostasis, which differs during pregnancy and lactation. Extra required calcium supply to the offspring in neither pregnancy nor breastfeeding normally do not cause any adverse consequences to the maternal skeleton even if any oral intake of calcium or vitamin D are increased. This article reviews the adaptation in calcium kinetics during pregnancy and lactation. Vitamin D, calciotropic hormones, and bone metabolism are also reviewed.

在孕期和哺乳期,钙的代谢发生了巨大的变化,因为后代需要钙的供应。大约30克的钙通过胎盘,在怀孕期间主要在妊娠晚期在胎儿体内积累,在哺乳期通过母乳提供220-340毫克/天的钙。然而,维持母体钙稳态的复杂机制在妊娠期和哺乳期有所不同。在妊娠期和哺乳期向后代提供额外所需的钙通常不会对母体骨骼造成任何不良后果,即使口服钙或维生素D摄入量增加。本文综述了妊娠期和哺乳期钙动力学的适应。对维生素D、促钙激素和骨代谢也进行了综述。
{"title":"[Calcium Metabolism and Skeletal Changes during Pregnancy and Lactation.]","authors":"Shun Yasuda,&nbsp;Hideki Mizunuma","doi":"CliCa19011926","DOIUrl":"https://doi.org/CliCa19011926","url":null,"abstract":"<p><p>Calcium metabolism changes dramatically during pregnancy and lactation because offspring needs a supply of calcium. Approximately 30g of calcium, which passes through the placenta, is accumulated in a fetus during pregnancy mostly in the third trimester, and 220-340mg/day of calcium is supplied via breast milk during lactation. However, there are elaborate mechanisms to maintain maternal calcium homeostasis, which differs during pregnancy and lactation. Extra required calcium supply to the offspring in neither pregnancy nor breastfeeding normally do not cause any adverse consequences to the maternal skeleton even if any oral intake of calcium or vitamin D are increased. This article reviews the adaptation in calcium kinetics during pregnancy and lactation. Vitamin D, calciotropic hormones, and bone metabolism are also reviewed.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"19-26"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36818592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pathophysiology of bone and calcium metabolism in young women.] [年轻女性骨和钙代谢的病理生理学]
Pub Date : 2019-01-01 DOI: CliCa19012734
Nahoko Shirato

In young women, why bone and calcium become a problem, it is because it is possible to delay the reach of the fracture threshold, even if the bone density in the future is acquired high bone density(bone mineral density:BMD)in the young period. In addition, the acquisition of maximum bone mass(peak bone mass:PBM)is an effective intervention to prevent future osteoporosis for around 18 years old before the age of 18. Factors that affect bone density include nutrition, dietary habits, physical activity, load movement, UV irradiation, estrogen deficiency, aging, and lifestyle-related diseases. In this section, it explains the condition and the disease which causes estrogen deficiency by low weight at an important time for the metabolism of the bone and calcium of young woman.

在年轻女性中,为什么骨钙成为一个问题,那是因为有可能延迟骨折阈值的到达,即使将来的骨密度是在年轻时期获得的高骨密度(骨矿物质密度:BMD)。此外,获得最大骨量(峰值骨量:PBM)是预防18岁前18岁左右骨质疏松的有效干预措施。影响骨密度的因素包括营养、饮食习惯、体力活动、负荷运动、紫外线照射、雌激素缺乏、衰老和与生活方式有关的疾病。在本节中,它解释了在年轻女性骨骼和钙代谢的重要时期,体重过轻导致雌激素缺乏的情况和疾病。
{"title":"[Pathophysiology of bone and calcium metabolism in young women.]","authors":"Nahoko Shirato","doi":"CliCa19012734","DOIUrl":"https://doi.org/CliCa19012734","url":null,"abstract":"<p><p>In young women, why bone and calcium become a problem, it is because it is possible to delay the reach of the fracture threshold, even if the bone density in the future is acquired high bone density(bone mineral density:BMD)in the young period. In addition, the acquisition of maximum bone mass(peak bone mass:PBM)is an effective intervention to prevent future osteoporosis for around 18 years old before the age of 18. Factors that affect bone density include nutrition, dietary habits, physical activity, load movement, UV irradiation, estrogen deficiency, aging, and lifestyle-related diseases. In this section, it explains the condition and the disease which causes estrogen deficiency by low weight at an important time for the metabolism of the bone and calcium of young woman.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"27-34"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36818593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Pharmacological treatment for pregnancy and lactation associated osteoporosis.] [妊娠和哺乳期骨质疏松症的药物治疗]
Pub Date : 2019-01-01 DOI: CliCa19017076
Maiko Kitajima, Osamu Chaki

Pregnancy and lactation associated osteoporosis(PLO)is a rare disorder for women during pregnancy, the post-partum period, or while breastfeeding. It still remains unknown factors in its pathogenesis. That makes it there is no evident strategy for PLO now. In most cases, bone mineral density(BMD)of PLO patients spontaneously recovers after giving lactation up. On the other hand, patients with severe cases sometimes need bone specific therapy. There are some reports that show bisphosphonate, teriparatide and/or denosumab are effective on PLO cases. When the patients have wishes for having babies, we have to pay attention if the prescription effect on next pregnancy.

妊娠和哺乳期相关骨质疏松症(PLO)是一种罕见的疾病,妇女在怀孕期间,产后时期,或在母乳喂养。其发病机制尚不清楚。这使得巴解组织目前没有明确的战略。大多数PLO患者的骨密度(BMD)在停乳后自发恢复。另一方面,重症患者有时需要骨特异性治疗。有一些报告显示,双膦酸盐、特立帕肽和/或地诺单抗对PLO病例有效。当患者有生育愿望时,我们要注意处方对下次怀孕是否有影响。
{"title":"[Pharmacological treatment for pregnancy and lactation associated osteoporosis.]","authors":"Maiko Kitajima,&nbsp;Osamu Chaki","doi":"CliCa19017076","DOIUrl":"https://doi.org/CliCa19017076","url":null,"abstract":"<p><p>Pregnancy and lactation associated osteoporosis(PLO)is a rare disorder for women during pregnancy, the post-partum period, or while breastfeeding. It still remains unknown factors in its pathogenesis. That makes it there is no evident strategy for PLO now. In most cases, bone mineral density(BMD)of PLO patients spontaneously recovers after giving lactation up. On the other hand, patients with severe cases sometimes need bone specific therapy. There are some reports that show bisphosphonate, teriparatide and/or denosumab are effective on PLO cases. When the patients have wishes for having babies, we have to pay attention if the prescription effect on next pregnancy.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"70-76"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36808013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[ASBMR 2018 Topics.] [ASBMR 2018主题。]
Pub Date : 2019-01-01 DOI: CliCa1901121124
Seiji Fukumoto

The annual meeting of ASBMR was held in Montr?al Convention Center between September 28th and October 1st, 2018. Many scientific papers concerning bone, mineral metabolism, muscle and so on were presented as usual. There were several new attempts such as discussion about clinically difficult cases and sessions for young scientists in this meeting. I will introduce several papers concerning cancer treatment-induced bone loss and treatment of patients with PTH-deficient hypoparathyroidism.

ASBMR年度会议在十一月举行。于2018年9月28日至10月1日期间在al会议中心举行。许多有关骨骼、矿物质代谢、肌肉等方面的科学论文照常发表。会议还增加了临床疑难病例讨论、青年科学家专题讨论等新的尝试。我将介绍几篇关于癌症治疗引起的骨质流失和甲状旁腺激素缺乏症患者治疗的论文。
{"title":"[ASBMR 2018 Topics.]","authors":"Seiji Fukumoto","doi":"CliCa1901121124","DOIUrl":"https://doi.org/CliCa1901121124","url":null,"abstract":"<p><p>The annual meeting of ASBMR was held in Montr?al Convention Center between September 28th and October 1st, 2018. Many scientific papers concerning bone, mineral metabolism, muscle and so on were presented as usual. There were several new attempts such as discussion about clinically difficult cases and sessions for young scientists in this meeting. I will introduce several papers concerning cancer treatment-induced bone loss and treatment of patients with PTH-deficient hypoparathyroidism.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 1","pages":"121-124"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36808021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The prevention and treatment of vascular calcification.] 【血管钙化的预防与治疗】
Pub Date : 2019-01-01 DOI: 10.20837/4201902231
Kazuki Kawakami, Masaki Ohya, Takashi Shigematsu

We had called the various bone disorder in chronic kidney disease(CKD)as a "ROD:renal osteodystrophy" until last decade. However the concept of ROD have changed into the chronic kidney disease-mineral and bone disease(CKD-MBD)within this decade. This concept is containing systemic disorder affected mortality. Vascular calcification is an independent risk factor for the development of cardiovascular disease and mortality. The best strategy to prevent and treat vascular calcification would consist of the CKD-MBD management. It is expected that the treatment of preventing directly vascular calcification to appear by finding the detailed mechanism in the future.

直到最近十年,我们一直将慢性肾脏疾病(CKD)中的各种骨骼疾病称为“ROD:肾性骨营养不良”。然而,近十年来,ROD的概念已经转变为慢性肾脏-矿物质和骨病(CKD-MBD)。这个概念包含了系统性疾病影响的死亡率。血管钙化是心血管疾病发展和死亡的独立危险因素。预防和治疗血管钙化的最佳策略是CKD-MBD的管理。通过对血管钙化机理的深入研究,有望在未来出现直接预防血管钙化的治疗方法。
{"title":"[The prevention and treatment of vascular calcification.]","authors":"Kazuki Kawakami,&nbsp;Masaki Ohya,&nbsp;Takashi Shigematsu","doi":"10.20837/4201902231","DOIUrl":"https://doi.org/10.20837/4201902231","url":null,"abstract":"<p><p>We had called the various bone disorder in chronic kidney disease(CKD)as a \"ROD:renal osteodystrophy\" until last decade. However the concept of ROD have changed into the chronic kidney disease-mineral and bone disease(CKD-MBD)within this decade. This concept is containing systemic disorder affected mortality. Vascular calcification is an independent risk factor for the development of cardiovascular disease and mortality. The best strategy to prevent and treat vascular calcification would consist of the CKD-MBD management. It is expected that the treatment of preventing directly vascular calcification to appear by finding the detailed mechanism in the future.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 2","pages":"231-236"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36895579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Wnt Signaling and Skeletal Dysplasias.] [Wnt信号与骨骼发育不良。]
Pub Date : 2019-01-01 DOI: 10.20837/4201903323
Toshimi Michigami

Identification of responsible genes for skeletal dysplasias evidences their critical roles in the skeletal development and maintenance. Mutations in the genes encoding the components of Wnt canonical pathway, which include WNT1, LRP5, LRP4, SOST and WTX, cause the disorders characterized by abnormal in bone mass. On the other hand, mutations in the genes for the components of Wnt non-canonical pathway such as WNT5A, ROR2, DVL1 and DVL3 are associated with dysmorphic skeletal disorders which manifest short limbs and facial anomalies. Thus, both canonical and non-canonical pathways of Wnt signaling play substantial roles in the human skeletons, and it is suggested that the former mainly controls bone mass while the latter regulates skeletal morphogenesis.

骨骼发育不良相关基因的鉴定证明了它们在骨骼发育和维持中的关键作用。编码Wnt典型通路组分的基因WNT1、LRP5、LRP4、SOST和WTX发生突变,导致以骨量异常为特征的疾病。另一方面,Wnt非规范通路组分基因如WNT5A、ROR2、DVL1和DVL3的突变与畸形骨骼疾病相关,这些疾病表现为四肢短和面部异常。由此可见,Wnt信号的规范通路和非规范通路在人类骨骼中都发挥着重要作用,提示前者主要控制骨量,后者调节骨骼形态发生。
{"title":"[Wnt Signaling and Skeletal Dysplasias.]","authors":"Toshimi Michigami","doi":"10.20837/4201903323","DOIUrl":"https://doi.org/10.20837/4201903323","url":null,"abstract":"<p><p>Identification of responsible genes for skeletal dysplasias evidences their critical roles in the skeletal development and maintenance. Mutations in the genes encoding the components of Wnt canonical pathway, which include <i>WNT1</i>, <i>LRP5</i>, <i>LRP4</i>, <i>SOST</i> and <i>WTX</i>, cause the disorders characterized by abnormal in bone mass. On the other hand, mutations in the genes for the components of Wnt non-canonical pathway such as <i>WNT5A</i>, <i>ROR2</i>, <i>DVL1</i> and <i>DVL3</i> are associated with dysmorphic skeletal disorders which manifest short limbs and facial anomalies. Thus, both canonical and non-canonical pathways of Wnt signaling play substantial roles in the human skeletons, and it is suggested that the former mainly controls bone mass while the latter regulates skeletal morphogenesis.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 3","pages":"323-328"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37007575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Control of inflammatory bone destruction by targeting the Wnt signaling pathway.] [通过靶向Wnt信号通路控制炎性骨破坏]
Pub Date : 2019-01-01 DOI: 10.20837/4201903337
Satoshi Soen

Bone erosions develop early in the course of rheumatoid arthritis(RA)and are predictive of a worse prognosis. They deteriorate gradually and cause joint damage, resulting in impaired functional capacity and disability. Lately, a considerable number of studies have increased our understanding of the pathogenic mechanisms participating in the development of bone erosions in RA. Osteoclasts are responsible cells and multiple factors have been identified to stimulate their differentiation and function. RANKL(receptor activator of NF-κB ligand)and other cytokines have been known for a long time to enhance osteoclastogenesis, but the role of other pathways has also been revealed recently. Besides to excessive ostaoclastogenesis, impair osteoblast differentiation and function also plays part in bone erosion formation in RA. Inflamed synovial membrane products increased levels of cytokines and antagonists of the canonical Wnt signaling pathway, which inhibit osteoblast differentiation and function. It seems that downregulation of this pathway leads to impaired osteoblast differentiation and activity and consequently, to reduced capacity of bone erosion to repair. Preclinical studies show that these findings could have implications in RA treatment, although more studies are required in this direction.

骨侵蚀在类风湿关节炎(RA)的早期发展,预示着较差的预后。它们逐渐恶化并引起关节损伤,导致功能受损和残疾。近年来,大量的研究增加了我们对类风湿关节炎骨侵蚀发病机制的认识。破骨细胞是负责任的细胞,多种因素已被确定刺激其分化和功能。RANKL(receptor activator of NF-κB ligand)等细胞因子促进破骨细胞发生的作用早已为人所知,但近年来其他途径的作用也被揭示出来。除破骨细胞生成过度外,成骨细胞分化和功能受损也参与了RA骨侵蚀的形成。炎症的滑膜产物增加了典型Wnt信号通路的细胞因子和拮抗剂水平,从而抑制成骨细胞的分化和功能。这一通路的下调似乎会导致成骨细胞分化和活性受损,从而降低骨侵蚀的修复能力。临床前研究表明,这些发现可能对类风湿关节炎的治疗有影响,尽管在这个方向上还需要更多的研究。
{"title":"[Control of inflammatory bone destruction by targeting the Wnt signaling pathway.]","authors":"Satoshi Soen","doi":"10.20837/4201903337","DOIUrl":"https://doi.org/10.20837/4201903337","url":null,"abstract":"<p><p>Bone erosions develop early in the course of rheumatoid arthritis(RA)and are predictive of a worse prognosis. They deteriorate gradually and cause joint damage, resulting in impaired functional capacity and disability. Lately, a considerable number of studies have increased our understanding of the pathogenic mechanisms participating in the development of bone erosions in RA. Osteoclasts are responsible cells and multiple factors have been identified to stimulate their differentiation and function. RANKL(receptor activator of NF-κB ligand)and other cytokines have been known for a long time to enhance osteoclastogenesis, but the role of other pathways has also been revealed recently. Besides to excessive ostaoclastogenesis, impair osteoblast differentiation and function also plays part in bone erosion formation in RA. Inflamed synovial membrane products increased levels of cytokines and antagonists of the canonical Wnt signaling pathway, which inhibit osteoblast differentiation and function. It seems that downregulation of this pathway leads to impaired osteoblast differentiation and activity and consequently, to reduced capacity of bone erosion to repair. Preclinical studies show that these findings could have implications in RA treatment, although more studies are required in this direction.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"29 3","pages":"337-341"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37007576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Clinical calcium
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1